Video

Dr. Randall on the Evolution of Limb Salvage Technologies in Bone Sarcomas

R. Lor Randall, MD, FACS, discusses the evolution of limb salvage technologies in bone sarcomas.

R. Lor Randall, MD, FACS, The David Linn Endowed Chair for Orthopaedic Surgery, professor and chair, Department of Orthopaedic Surgery, University of California Davis Health, discusses the evolution of limb salvage technologies in bone sarcomas.

Cemented stem and press-fit implants were useful limb salvage technologies initially; however, over time, stress shielding causes many of these endoprostheses to become loose at the stem interface, Randall explains. This loosening eventually causes the limb to fail and cause pain, fractures, and other morbid complications.

Before the integration of neoadjuvant and adjuvant chemotherapy, patients with bone sarcomas were likely to succumb to their disease, so short-term benefits from limb salvage technology were usually sufficient. However, chemotherapy had prolonged survival so that patients were outliving their disease, Randall says. Therefore, limb salvage technologies that caused eventual orthopedic disease needed to be improved upon.

As such, compressive osseointegration is a novel technique that harnesses Wolff’s law to allow the bone to adapt and grow in response to physical force, Randall concludes.

Related Videos
Viktor Grünwald, MD, PhD
Aaron Gerds, MD
Christine M. Lovly, MD, PhD, Ingram Associate Professor of Cancer Research, associate professor, medicine (hematology/oncology), Vanderbilt-Ingram Cancer Center
Haeseong Park, MD, MPH
David L. Porter, MD
Timothy Yap, MBBS, PhD, FRCP
Leo I. Gordon, MD, Abby and John Friend Professor of Oncology Research, professor, medicine (hematology and oncology), Feinberg School of Medicine, Robert H. Lurie Cancer Center
Hetty E. Carraway, MD, MBA, staff associate professor, Department of Medicine, School of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University; member, Immune Oncology Program, Case Comprehensive Cancer Center; vice chair, Strategy and Enterprise Development, Taussig Cancer Institute, Division of Hematologic Oncology and Blood Disorders, Cleveland Clinic
David A. Braun, MD, PhD, assistant professor, medicine (medical oncology), Louis Goodman and Alfred Gilman Yale Scholar, member, Center of Molecular and Cellular Oncology, Yale Cancer Center
Julia Foldi, MD, PhD